Literature DB >> 28889385

The N-butyl-N-4-hydroxybutyl Nitrosamine Mouse Urinary Bladder Cancer Model.

Paula A Oliveira1,2, Cármen Vasconcelos-Nóbrega3, Rui M Gil da Costa4,5, Regina Arantes-Rodrigues4,5.   

Abstract

Urinary bladder cancer (UBC) is a common and complex malignancy, with a multifactorial etiology, like environmental factors, such as cigarette smoking, occupational exposure, and genetic factors.UBC exhibits considerable genotypic and phenotypic heterogeneity. Among all UBC lesions, urothelial carcinoma is the most frequently observed histological type. Despite all the developments made in urologic oncology field, therapeutic options remain inadequate. There is urgency for the identification and development of new antineoplastic drugs to replace or improve current protocols and in vivo models have been proven to be essential for this step. There are different animal models of UBC: Spontaneous and experimentally induced models (genetically engineered, transplantable-xenograft and syngeneic animals- and chemically induced models). N-butyl-N(4-hydroxybutil)nitrosamine (BBN) is the most suitable reagent to generate chemically induced in vivo models of UBC and to study bladder carcinogenesis. BBN has proven, over the years, to be very realistic and reliable. It is bladder specific, and induces high tumor incidence.

Entities:  

Keywords:  Animal models; Arylamines; Bladder cancer; Chemical carcinogenesis

Mesh:

Substances:

Year:  2018        PMID: 28889385     DOI: 10.1007/978-1-4939-7234-0_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

1.  BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer.

Authors:  Aleksandar Obradovic; Alok Kumar Singh; Kara A Lombardo; James L Liu; Gregory Joice; Max Kates; William Bishai; David McConkey; Alcides Chaux; Marie-Lisa Eich; M Katayoon Rezaei; George J Netto; Charles G Drake; Phuoc Tran; Andres Matoso; Trinity J Bivalacqua
Journal:  J Pathol       Date:  2021-12-10       Impact factor: 7.996

Review 2.  Preclinical Models for Bladder Cancer Research.

Authors:  Shaoming Zhu; Zheng Zhu; Ai-Hong Ma; Guru P Sonpavde; Fan Cheng; Chong-Xian Pan
Journal:  Hematol Oncol Clin North Am       Date:  2021-04-16       Impact factor: 2.861

3.  Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines.

Authors:  Tahlita C M Zuiverloon; Florus C de Jong; James C Costello; Dan Theodorescu
Journal:  Bladder Cancer       Date:  2018-04-26

4.  Association of Glutathione S-transferase gene polymorphism with bladder Cancer susceptibility.

Authors:  Tianbiao Zhou; Hong-Yan Li; Wei-Ji Xie; Zhiqing Zhong; Hongzhen Zhong; Zhi-Jun Lin
Journal:  BMC Cancer       Date:  2018-11-12       Impact factor: 4.430

5.  Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model.

Authors:  Hideki Furuya; Owen T M Chan; Ian Pagano; Chengjun Zhu; Nari Kim; Rafael Peres; Kanani Hokutan; Sarah Alter; Peter Rhode; Charles J Rosser
Journal:  J Transl Med       Date:  2019-01-17       Impact factor: 5.531

6.  Sex differences in the aging murine urinary bladder and influence on the tumor immune microenvironment of a carcinogen-induced model of bladder cancer.

Authors:  Ali Hamade; Deyang Li; Kathrin Tyryshkin; Minqi Xu; Gwenaelle Conseil; Priyanka Yolmo; Jake Hamilton; Stephen Chenard; D Robert Siemens; Madhuri Koti
Journal:  Biol Sex Differ       Date:  2022-05-03       Impact factor: 5.027

7.  Construction and application of urinary system model with functional bladder module.

Authors:  Min Liu; Yonghong Su
Journal:  Saudi J Biol Sci       Date:  2019-10-16       Impact factor: 4.219

Review 8.  Molecular Markers in Urinary Bladder Cancer: Applications for Diagnosis, Prognosis and Therapy.

Authors:  Ana Mafalda Rasteiro; Eva Sá E Lemos; Paula A Oliveira; Rui M Gil da Costa
Journal:  Vet Sci       Date:  2022-02-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.